Myelodysplastic Syndrome

Trisenox and thalidomide produce multi-lineage hematologic responses in MDS

Published in Cancer Weekly, June 15th, 2004

A study by A. Raza, MD, of Rush Medical Center, published in Leukemia Research, concluded that the combination of Trisenox (arsenic trioxide) injection and thalidomide in patients with myelodysplastic syndrome (MDS) produced multi-lineage hematologic responses in 25% of patients studied.

A separate study by M. Hussein, MD, of the Cleveland Clinic Foundation, published in the British Journal of Haematology, showed that Trisenox as a monotherapy resulted in a clinical benefit to patients with relapsed or refractory multiple myeloma with objective responses in 33% of patients studied.

Cell Therapeutics, Inc., markets Trisenox in the U.S....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-06-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry